Fundz Deep Dive
Everything you need to win Myriad Genetics — in one platform.
Who to reach, what to say, and why now on Myriad Genetics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Myriad Genetics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
MD Anderson and Myriad Genetics Partner to Evaluate Clinical Utility of Molecular Residual Disease Assay
Jan 07, 2025•over 1 year ago
Contract Type
partnership
Salt Lake CityBiotechnologyHealth CareMedicalDescription
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. have announced a strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. The alliance aims to create studies to evaluate the clinical validity and utility of Myriad’s Precise MRD.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months